Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
  • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/49—Cinchonan derivatives, e.g. quinine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
  • C07C51/41—Preparation of salts of carboxylic acids
  • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to a method of preparing solifenacin or a salt thereof. More particularly, the present invention relates to a method of preparing a novel solifenacin intermediate and a method of preparing solifenacin or a salt thereof using the intermediate.
• Solifenacin succinate ((1S)-(3R)-1-azabicyclo[2,2,2]oct-3-yl-3,4-dihydro-1-phenyl-2(1H)-isoquinoline carboxylate succinate), represented by Formula (I) below, is a competitive and selective M3 muscarine receptor antagonist, and is known as a compound used to treat overactive bladder symptoms such as urgent urinary incontinence, urinary urgency, urinary frequency and the like.
• U.S Patent No. 6,017,927 discloses two synthesis pathways for preparing solifenacin, synthesis pathway A and synthesis pathway B represented by Reaction Formula 1 below.
• the method of preparing solifenacin using the synthesis pathway A and synthesis pathway B is problematic in that it requires high cost, its efficiency is not high due to post-treatment processes, and it is not suitable for producing solifenacin on an industrial scale.
• ethyl carboxylate used in the synthesis pathway A produces ethanol as a by-product of a transesterification reaction.
• ethanol initiates a nucleophilic attack against solifenacin in the presence of a base, in order to continue the reaction, there is a problem in that ethanol must be separated from a reaction system using an azeotrope with toluene or a method related thereto, which is very industrially difficult.
• the synthesis pathway A is also problematic in that it is difficult to obtain solifenacin having high optical purity because solifenacin is racemized.
• solifenacin is prepared through an intermediate, which is formed from (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline with a leaving group(Lv) such as 1H-imidazole-1-yl, 2,5-dioxopyrrolidine-1-yloxy, 3-methyl-1H-imidazol-3-lium-1-yl or chloride and then conducted a condensation reaction with (R)-quinuclidinol in a mixed solvent of toluene and dimethylsulfoxide or in a single solvent of toluene by refluxing and stirring in the presence of sodium hydride (NaH).
• Lv leaving group
• the present inventors have devised a high yield method of preparing solifenacin or a salt thereof, in which high-purity solifenacin or a salt thereof can be simply and efficiently prepared at room temperature without using a base, and which can be industrially used.
• An object of the present invention is to provide a method of preparing high-purity solifenacin or a salt thereof with high yield.
• Another object of the present invention is to provide a method of preparing solifenacin or a salt thereof in large amounts by a simple process.
• Still another object of the present invention is to provide a novel intermediate used in the method and a method of preparing the novel intermediate.
• an aspect of the present invention provides a method of preparing solifenacin or a salt thereof, comprising the steps of: (a) reacting (R)-quinuclidinol of Formula (VI) below with bis(pentafluorophenyl)carbonate of Formula (VII) below in an organic solvent to prepare (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate of Formula (IV) below; and (b) reacting the (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate of Formula (IV) below with (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline of Formula (V) below in an organic solvent to prepare solifenacin of Formula (II) below:
• Another aspect of the present invention provides a compound represented by Formula (IV) below, which is used as an intermediate for preparing solifenacin:
• Still another aspect of the present invention provides a method of preparing a compound of Formula (IV) below, comprising the step of reacting (R)-quinuclidinol of Formula (VI) below with bis(pentafluorophenyl)carbonate of Formula (VII) below in an organic solvent.
• the present invention can provide a method of preparing high purity solifenacin or a salt thereof with high yield.
• the present invention can provide a method of preparing solifenacin or a salt thereof that can produce large amounts by a simple process.
• the present invention can provide a novel intermediate and a method of preparing the novel intermediate used in the process.
• the present invention provides a novel synthesis pathway for preparing solifenacin or a salt thereof, represented by Reaction Formula 4 below:
• the method of preparing solifenacin or a salt thereof according to the present invention includes the steps of: (a) preparing a solifenacin intermediate; (b) preparing solifenacin using the intermediate; and (c) converting the solifenacin into a solifenacin salt.
• the present invention provides a method of preparing (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate of Formula (IV) below, which can be used as an intermediate for preparing solifenacin or a salt thereof:
• the solifenacin intermediate is prepared by reacting (R)-quinuclidinol of Formula (VI) below with bis(pentafluorophenyl)carbonate of Formula (VII) below in an organic solvent, as shown in Reaction Formula 5 below:
• the bis(pentafluorophenyl)carbonate of Formula (VII) can be used at an amount of 1 to 3 molar equivalent per 1 molar equivalent of (R)-quinuclidinol of Formula (VI), preferably 1 to 1.5 molar equivalent.
• the organic solvent can be selected from the group including of toluene, ethyl acetate, dichloromethane, acetone, isopropanol and mixtures thereof.
• the organic solvent can be used at an amount of 2 mL to 20 mL per l g of (R)-quinuclidinol of Formula (VI), and preferably 5 ml to 15 mL.
• the reaction of Reaction Formula 5 above may be performed at -40 °C to 100 °C, and preferably 10 °C to 30 °C. Particularly, the reaction of Reaction Formula 5 may be performed at room temperature, and thus this reaction can be performed under moderate conditions without conducting an additional process such as heating, cooling or the like.
• reaction of Reaction Formula 5 be performed for 2 hours to 12 hours at the mentioned temperature.
• reaction of Reaction Formula 5 may be performed without using any base or catalyst even under the moderate conditions.
• the solifenacin intermediate of Formula (IV) can be obtained with high yield of more than 87% under the moderate reaction conditions.
• the present invention provides a method of preparing solifenacine by reacting the solifenacin intermediate of Formula (IV) prepared in the step (a) with (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline of Formula (V) below in an organic solvent, as shown in Reaction Formula 6 below:
• reaction of Reaction Formula 6 above may be performed by an in-situ reaction in which the (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline of Formula (V) is added dropwise without dissociating the (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate of Formula (IV) prepared in the step (a).
• the (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline of Formula (V) can be used at an amount of 1 to 3 molar equivalent per 1 molar equivalent of (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate of Formula (IV), preferably 1 to 1.5 molar equivalent.
• the organic solvent just like in the step (a), may be selected from the group including of toluene, ethyl acetate, dichloromethane, acetone, isopropanol and mixtures thereof. Further, the organic solvent in the step (b) may be same with that of in the step (a).
• the reaction of Reaction Formula 6 above may be performed at -40 °C to 100 °C, and preferably, 10 °C to 30 °C. Particularly, the reaction of Reaction Formula 6 may be performed at room temperature, and thus this reaction can be performed under moderate conditions without conducting an additional process such as heating, cooling or the like.
• reaction of Reaction Formula 6 be performed for 2 hours to 12 hours at the mentioned temperature.
• reaction of Reaction Formula 6 may be performed without using any base or catalyst even under the moderate conditions.
• the solifenacin of Formula (II) can be obtained by the following purification process. Specifically, water is added to the solution obtained after the completion of the reaction of Reaction Formula 6, a strong acid such as hydrochloric acid is added dropwise into the solution to adjust the pH of the solution to 1 ⁇ 2, an organic layer is separated from the solution to remove pentafluorophenol produced during the reaction, a base such as ammonium hydroxide is further dripped into the solution to adjust the pH of the solution to 9 ⁇ 10, the solution is extracted with toluene, and then the extracted solution is concentrated, thereby obtain oily solifenacin.
• a strong acid such as hydrochloric acid
• an organic layer is separated from the solution to remove pentafluorophenol produced during the reaction
• a base such as ammonium hydroxide is further dripped into the solution to adjust the pH of the solution to 9 ⁇ 10
• the solution is extracted with toluene, and then the extracted solution is concentrated, thereby obtain oily solifenacin.
• the solifenacin of Formula (II) can be obtained with high yield of more than 87% under the moderate reaction conditions.
• the present invention provides a method of converting the solifenacin of Formula (II) prepared in the step (b) into a salt thereof.
• the salt of solifenacin may be an acid addition salt prepared by reacting the solifenacin of Formula (II) prepared in the step (b) with an inorganic or organic acid in an organic solvent.
• the inorganic acid may be hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid or the like.
• the organic acid may be formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid, glutamic acid or the like.
• the organic acid may be succinic acid.
• Examples of the organic solvent used in the reaction of Reaction Formula 7 may include: aliphatic alcohols, such as ethanol, 1-butanol, isopropanol and the like; ketones, such as acetone, methyl isobutyl ketone, and the like; esters, such as ethyl acetate, n-butyl acetate, ethyl propionate, and the like; aromatic hydrocarbons, such as tolune and the like; and polar aliphatic hydrocarbons, such as n-hexane, heptane, and the like.
• acetone, toluene or a mixture thereof may be used as the organic solvent.
• the reaction of Reaction Formula 7 may be performed by stirring the reaction mixture at 50 °C ⁇ 65 °C for 20 minutes ⁇ 1 hour and then further stirring the reaction mixture at 10 °C ⁇ 15°C for 1 hour ⁇ 3 hours.
• solifenacin succinate When the reaction is completed, the prepared solifenacin is filtered, washed and then dried to obtain solifenacin succinate.
• the solifenacin succinate obtained in this way may be crystalline solifenacin succinate, and this crystalline solifenacin succinate has a melting point of 146 °C ⁇ 148 °C.
• the solifenacin succinate of Formula (I) can be obtained with high yield of more than 78%.
• the present invention provides a novel intermediate represented by Formula (IV) below, which can be used to prepare solifenacin and a salt thereof, and a method of preparing the intermediate:
• the method of preparing a solifenacin intermediate is the same as the step (a) of the method of preparing solifenacin or a salt thereof.
• the solifenacin intermediate is a material which can be simply and efficiently prepared at room temperature without using a base by the step (a). Further, the solifenacin intermediate is used as a reactant in the step (b), and can be easily converted into solifenacin at room temperature without using a base.
• the method of preparing solifenacin or a salt thereof using a solifenacin intermediate is advantageous in that high-purity solifenacin or a salt thereof can be prepared with high yield by a simple process.
• solifenacin intermediate of Formula (IV) can be used to produce solifenacin or a salt thereof in large amounts.
• reaction solution was washed with 1270 mL of water, dried with MgSO 4 and then concentrated under reduced pressure to obtain 304.9 g (90.4%) of (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate.
• reaction solution was washed with 1270 mL of water, dried with MgSO 4 and then concentrated under reduced pressure to obtain 300.8 g (89.2%) of (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate.
• reaction solution was washed with 1270 mL of water, dried with MgSO 4 and then concentrated under reduced pressure to obtain 298.1 g (88.4%) of (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate.
• reaction solution was washed with 1270 mL of water, dried with MgSO 4 and then concentrated under reduced pressure to obtain 295.4 g (87.6%) of (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate.
• reaction solution was washed with 1400 mL of water, dried with MgSO 4 and then concentrated under reduced pressure to obtain 320.4 g (88.4%) of solifenacin.
• reaction solution was washed with 1400 mL of water, dried with MgSO 4 and then concentrated under reduced pressure to obtain 318.2 g (87.8%) of solifenacin.
• reaction solution was washed with 1400 mL of water, dried with MgSO 4 and then concentrated under reduced pressure to obtain 320.4 g (88.4%) of solifenacin.
• reaction solution was washed with 1400 mL of water, dried with MgSO 4 and then concentrated under reduced pressure to obtain 220.4 g (88.4%) of solifenacin.
• reaction solution was washed with 1270 mL of toluene to remove pentafluorophenol (a by-product formed during the reaction) from the reaction product. Then, an aqueous layer was extracted from the reaction solution using 1270 mL of dichloromethane, and then the reaction solution was concentrated under reduced pressure. Then, 1270 mL of water was added to the reaction solution, the pH of the reaction solution was adjusted to 9 ⁇ 10 using ammonium hydroxide, and then an aqueous layer was further extracted from the reaction solution using 1270 mL of toluene.
• reaction solution was washed with 1270 mL of toluene to remove pentafluorophenol (a by-product formed during the reaction) from the reaction product. Then, an aqueous layer was extracted from the reaction solution using 1270 mL of dichloromethane, and then the reaction solution was concentrated under reduced pressure. Then, 1270 mL of water was added to the reaction solution, the pH of the reaction solution was adjusted to 9 ⁇ 10 using ammonium hydroxide, and then an aqueous layer was further extracted from the reaction solution using 1270 mL of toluene.
• melting point, elementary analysis and spectral data are the same as those of Example 11.
• reaction solution was washed with 1270 mL of toluene to remove pentafluorophenol (a by-product formed during the reaction) from the reaction product. Then, an aqueous layer was extracted from the reaction solution using 1270 mL of dichloromethane, and then the reaction solution was concentrated under reduced pressure. Then, 1270 mL of water was added to the reaction solution, the pH of the reaction solution was adjusted to 9 ⁇ 10 using ammonium hydroxide, and then an aqueous layer was further extracted from the reaction solution using 1270 mL of toluene.
• melting point, elementary analysis and spectral data are the same as those of Example 11.
• reaction solution was washed with 1270 mL of toluene to remove pentafluorophenol (a by-product formed during the reaction) from the reaction product. Then, an aqueous layer was extracted from the reaction solution using 1270 mL of dichloromethane, and then the reaction solution was concentrated under reduced pressure. Then, 1270 mL of water was added to the reaction solution, the pH of the reaction solution was adjusted to 9 ⁇ 10 using ammonium hydroxide, and then an aqueous layer was further extracted from the reaction solution using 1270 mL of toluene.
• melting point, elementary analysis and spectral data are the same as those of Example 11.
• reaction solution was washed with 1270 mL of toluene to remove pentafluorophenol (a by-product formed during the reaction) from the reaction product. Then, an aqueous layer was extracted from the reaction solution using 1270 mL of dichloromethane, and then the reaction solution was concentrated under reduced pressure. Then, 1270 mL of water was added to the reaction solution, the pH of the reaction solution was adjusted to 9 ⁇ 10 using ammonium hydroxide, and then an aqueous layer was further extracted from the reaction solution using 1270 mL of toluene.
• melting point, elementary analysis and spectral data are the same as those of Example 11.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Urology & Nephrology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=49260649

Family Applications (1)

Country Status (9)

Families Citing this family (1)

Citations (4)

Family Cites Families (13)

• 2012
  • 2012-03-28 KR KR20120031492A patent/KR101365849B1/ko active Active
• 2013
  • 2013-03-21 EP EP13768214.2A patent/EP2831070A4/en not_active Withdrawn
  • 2013-03-21 AU AU2013240842A patent/AU2013240842B2/en not_active Ceased
  • 2013-03-21 WO PCT/KR2013/002358 patent/WO2013147458A1/en not_active Ceased
  • 2013-03-21 CN CN201380016063.XA patent/CN104169280A/zh active Pending
  • 2013-03-21 US US14/382,529 patent/US9018379B1/en not_active Expired - Fee Related
  • 2013-03-21 IN IN7762DEN2014 patent/IN2014DN07762A/en unknown
  • 2013-03-21 BR BR112014021223-6A patent/BR112014021223A2/pt not_active IP Right Cessation
  • 2013-03-21 JP JP2015501582A patent/JP5891334B2/ja active Active

Patent Citations (4)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events